Open AccessSafety, Immunogenicity, and Immune Memory of a Novel Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (MCV-4) in Healthy Adolescents
Author(s) -
Harry Keyserling,
Thomas Papa,
Katalin Koranyi,
Robert Ryall,
Ehab Bassily,
Michael J. Bybel,
Kevin M. Sullivan,
Gregory Gilmet,
Al Reinhardt
Publication year - 2005
Publication title -
archives of pediatrics and adolescent medicine
Language(s) - English
Resource type - Journals
eISSN - 1538-3628
pISSN - 1072-4710
DOI - 10.1001/archpedi.159.10.907
Subject(s) - immunogenicity , toxoid , medicine , vaccination , conjugate vaccine , immunology , reactogenicity , tetanus , diphtheria , booster dose , antibody , diphtheria toxin , tolerability , meningococcal vaccine , titer , immunization , microbiology and biotechnology , adverse effect , biology , toxin
A meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4; Menactra; Sanofi Pasteur Inc, Swiftwater, Pa) was developed to improve the profile of currently licensed products. The objective of this study was to compare the tolerability, immunogenicity, and immune memory of MCV-4 with those of a quadrivalent polysaccharide vaccine (PSV-4; Menomune A/C/Y/W-135; Sanofi Pasteur Inc).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom